Song Yue, Xin Xing, Xia Zhijun, Zhai Xingyue, Shen Keng
Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang 110004, P.R. China.
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Oncol Rep. 2014 Jul;32(1):225-34. doi: 10.3892/or.2014.3204. Epub 2014 May 20.
The objective of our study was to construct recombinant adenovirus (rAd) AdHTVP2G5-rev-casp3, which expresses autocatalytic caspase-3 driven by human telomerase reverse transcriptase promoter (hTERTp) with a two-step transcription amplification (TSTA) system and investigate its antitumor effects on ovarian cancer in vitro and in vivo. Fluorescent detection was used to detect EGFP expression in various cells. Cell viabilities were determined using the Cell Counting Kit-8 and flow cytometry. RT-PCR and immunoblotting assays were used to detect cellular apoptotic activities. Tumor growth and survival of tumor-bearing mice were studied. The hTERTp-TSTA system showed the strongest activity in hTERT-positive cancer cells when compared with hTERTp and cytomeglovirus promoter (CMVp). In contrast, it showed no activity in hTERT‑negative HUVECs. AdHTVP2G5‑rev-casp3 markedly suppressed the survival of AO cells in a dose-dependent modality with a viability rate of 17.8 ± 3.5% at an MOI of 70, which was significantly lower than that by AdHT-rev-casp3 and Ad-rev-casp3 (rAds which express rev-caspase-3 driven by hTERTp and CMVp, respectively). In contrast, AdHTVP2G5‑rev-casp3 induced little HUVEC death with a viability rate of 92.7 ± 5.2% at the same MOI. Additionally, AdHTVP2G5-rev-casp3 (MOI=70) caused significant apoptosis in AO cells with an apoptotic rate of 42%. The tumor growth suppression rate of AdHTVP2G5-rev-casp3 was 81.52%, significantly higher than that of AdHT-rev-casp3 (54.94%) or Ad-rev-casp3 (21.35%). AdHTVP2G5-rev-casp3 significantly improved the survival of tumor-bearing mice with little liver damage, with a mean survival of 258 ± 28 days. These results showed that AdHTVP2G5-rev-casp3 caused effective apoptosis with significant tumor selectivity, strongly suppressed tumor growth and improved mouse survival with little liver toxicity. It can be a potent therapeutic agent for tumor targeted treatment of ovarian cancer.
我们研究的目的是构建重组腺病毒(rAd)AdHTVP2G5-rev-casp3,其通过人端粒酶逆转录酶启动子(hTERTp)驱动的自催化半胱天冬酶-3表达,并带有两步转录扩增(TSTA)系统,同时研究其在体外和体内对卵巢癌的抗肿瘤作用。采用荧光检测法检测各种细胞中的EGFP表达。使用细胞计数试剂盒-8和流式细胞术测定细胞活力。采用RT-PCR和免疫印迹分析检测细胞凋亡活性。研究荷瘤小鼠的肿瘤生长和存活情况。与hTERTp和巨细胞病毒启动子(CMVp)相比,hTERTp-TSTA系统在hTERT阳性癌细胞中表现出最强的活性。相反,它在hTERT阴性的人脐静脉内皮细胞(HUVECs)中无活性。AdHTVP2G5-rev-casp3以剂量依赖性方式显著抑制AO细胞的存活,在MOI为70时存活率为17.8±3.5%,明显低于AdHT-rev-casp3和Ad-rev-casp3(分别由hTERTp和CMVp驱动表达rev-半胱天冬酶-3的重组腺病毒)。相反,在相同MOI下,AdHTVP2G5-rev-casp3诱导HUVEC死亡较少,存活率为92.7±5.2%。此外,AdHTVP2G5-rev-casp3(MOI = 70)导致AO细胞显著凋亡,凋亡率为42%。AdHTVP2G5-rev-casp3的肿瘤生长抑制率为81.52%,显著高于AdHT-rev-casp3(54.94%)或Ad-rev-casp3(21.35%)。AdHTVP2G5-rev-casp3显著提高荷瘤小鼠的存活率,且肝脏损伤较小,平均存活时间为258±28天。这些结果表明,AdHTVP2G5-rev-casp3能有效诱导凋亡,具有显著的肿瘤选择性,强烈抑制肿瘤生长并提高小鼠存活率,且肝脏毒性较小。它可能是一种用于卵巢癌肿瘤靶向治疗的有效治疗剂。